5 results
Our primary aim is to assess the (cost-)effects of the ACCESS system in the support of exacerbation self-management of patients with COPD.
To characterize the safety, tolerability, and recommended phase 2 dose (RP2D) of each combination partner used with ruxolitinib (Part 1)To evaluate the preliminary efficacy of each novel ruxolitinib combination treatment arm (Parts 2 & 3)
To study the effect of crizanlizumab on the hemodynamics of the cerebral vasculature (CBF and CVR)
The main objective of this study is to investigate the neural basis of cognitive processing in awake behaving patients. The main focus will be on memory processes in the medial temporal lobe (MTL), emotional processing in the insular cortex and…
To evaluate the effect of crizanlizumab + standard of care compared to standard of care alone on albuminuria (ACR) decrease at 12 months